Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAY RE-HIT study of ianalumab retreatment in adults with relapsed primary immune thrombocytopenia or warm autoimmune hemolytic anemia who previously benefited from ianalumab
CTR20254290Phase 2Terminated
- Sponsor
- Novartis
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ianalumab in immune thrombocytopenia (ITP), warm autoimmune hemolytic anemia (wAIHA), sponsored by Novartis. Started Oct 2025; status: terminated.
02
Drugs
ianalumab
03
Conditions
immune thrombocytopenia (ITP)warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on CTR20254290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254290.